Factors associated to persistence of treatment with Golimumab in the BIOBADASER registry, with up to 6 years of follow-up
14/08/2023
Manuel Pombo1, Carlos Sánchez-Piedra2, Eduardo Cuende3, Raquel Martín-Domenech4, Javier del Pino5, Cristina Campos Fernández6, Javier Manero7, Blanca Garcia-Magallon8, Fernando Sánchez-Alonso2, Federico Diaz-Gonzalez9, María J. Arteaga10, Luis Cea-Calvo10, J Juan1, Gómez-Reino
EULAR 2019
DOI: 10.1136/annrheumdis-2019-eular.2751
http://scientific.sparx-ip.net/archiveeular/?c=a&searchfor=biobadaser&view=2&item=2019SAT0158